Every figure below is transcribed from published literature (peptideprotocolportal.com, compiled 2026-09-29). None of it is a recommendation, a protocol, or a target, and none of it was written here. Whether any of it applies to a person is a question for a licensed clinician — who this is for explains why.
Cautions
The source records no specific caution for Tirzepatide (GLP-1/GIP). That is a fact about the document rather than about the compound: it means this table does not state one, not that none exists. The general exclusions on who this is for apply to everything in this reference.
All 5 presentations, as reported
The source lists this compound once per vial size. All of them are shown rather than one chosen for you, because the ranges differ between them.
| Vial | Dose | Frequency | Route |
|---|---|---|---|
| 5mg | 2.5-15mg (titrate) | 1x/week | SubQ |
| 10mg | 2.5-15mg (titrate) | 1x/week | SubQ |
| 15mg | 2.5-15mg (titrate) | 1x/week | SubQ |
| 30mg | 2.5-15mg (titrate) | 1x/week | SubQ |
| 60mg | 2.5-15mg (titrate) | 1x/week | SubQ |
The source's own notes
Reproduced in full, including the parts that are description rather than caution. Trimming this column for layout would remove its harm-reduction payload.
Same day every week. Starting dose 2.5mg
Before anything else
A compound's paperwork is the part you can actually verify. Reading a Certificate of Analysis and what a COA cannot tell you cover both halves of that, and inspecting a vial on arrival covers what to check before a vial is opened at all.